Merck & Co Inc’s (MRK) patritumab deruxtecan demonstrated statistically significant improvement in progression-free survival compared to standard chemotherapy in a Phase 3 trial for EGFR-mutated non-small cell lung cancer (NSCLC). This positive outcome comes as Summit Therapeutics Inc’s (SMMT) ivonescimab also showed promising results against Merck’s Keytruda (pembrolizumab) in a separate lung cancer trial.